Larimar Therapeutics (LRMR) Common Equity (2013 - 2026)
Larimar Therapeutics (LRMR) recorded Common Equity of $127.38 million in Q2 2026, up 6.3% from $119.85 million a year earlier.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Common Equity (2013 - 2026) Analysis & Trends
At the end of FY2025, Larimar Therapeutics reported Common Equity of $78.09 million, down 54.6% from FY2024.
- Annual Common Equity has a five-year compound annual growth rate of -2.7% (FY2020 to FY2025).
- Across earlier years, Common Equity came in at $171.81 million in FY2024 (+110.2%), $81.72 million in FY2023 (-26.3%), $110.9 million in FY2022 (+72.2%) and $64.41 million in FY2021 (-28.2%).
- Quarterly Common Equity has ranged from $50.06 million in Q2 2022 to $230.84 million in Q1 2024 over the past five years.
- On a year-over-year basis, Common Equity rose in three of the last seven quarters, with growth averaging 9.3%.
- Peak year-over-year performance for Common Equity in the last five years was growth of 117.3% in Q1 2024, against a decline of 54.6% in Q4 2025 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Larimar Therapeutics | 329.31 Mn | -277.77 Mn | - | 127.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 127.38 Mn |
| Dec 31, 2025 | 78.09 Mn |
| Sep 30, 2025 | 139.04 Mn |
| Jun 30, 2025 | 119.85 Mn |
| Mar 31, 2025 | 144.27 Mn |
| Dec 31, 2024 | 171.81 Mn |
| Sep 30, 2024 | 198.40 Mn |
| Jun 30, 2024 | 211.40 Mn |
| Mar 31, 2024 | 230.84 Mn |
| Dec 31, 2023 | 81.72 Mn |
| Sep 30, 2023 | 92.71 Mn |
| Jun 30, 2023 | 99.93 Mn |
| Mar 31, 2023 | 106.24 Mn |
| Dec 31, 2022 | 110.90 Mn |
| Sep 30, 2022 | 118.66 Mn |
| Jun 30, 2022 | 50.06 Mn |
| Mar 31, 2022 | 57.11 Mn |
| Dec 31, 2021 | 64.41 Mn |
| Sep 30, 2021 | 72.07 Mn |
| Jun 30, 2021 | 67.53 Mn |
API Access
Larimar Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=LRMR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "LRMR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=LRMR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();